| The Data and Safety Monitoring Board said in a statement Tuesday that it was concerned that AstraZeneca may have provided an incomplete view of the efficacy data for its vaccine. AstraZeneca reported Monday that its vaccine provided strong protection among adults of all ages, a finding that could help move it a step closer to clearance for use in the U.S. |  |
News Alert Tuesday, March 23 |
|
| | | | | | | | |
|
